Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial

OBJECTIVE: In the SENSCIS trial in subjects with systemic sclerosis–associated interstitial lung disease (SSc‐ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Maher, Toby M., Mayes, Maureen D., Kreuter, Michael, Volkmann, Elizabeth R., Aringer, Martin, Castellvi, Ivan, Cutolo, Maurizio, Stock, Christian, Schoof, Nils, Alves, Margarida, Raghu, Ganesh
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Systemic Sclerosis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048624/
https://ncbi.nlm.nih.gov/pubmed/33142016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.41576
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados